SS31 Ameliorates Podocyte Injury via Inhibiting OMA1-Mediated Hydrolysis of OPA1 in Diabetic Kidney Disease
Diabetic kidney disease (DKD) is currently one of the leading causes of end-stage renal disease (ESRD). Mitochondrial dysfunction in podocyte is involve in DKD development. However, whether early mitochondrial stabilization delays or reverses DKD progression has not been elucidated. SS31 is a novel...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.707006/full |
| _version_ | 1811330180395827200 |
|---|---|
| author | Qianqian Yang Wenjia Xie Xiao Wang Jing Luo Yang Zhou Hongdi Cao Qi Sun Lei Jiang Junwei Yang |
| author_facet | Qianqian Yang Wenjia Xie Xiao Wang Jing Luo Yang Zhou Hongdi Cao Qi Sun Lei Jiang Junwei Yang |
| author_sort | Qianqian Yang |
| collection | DOAJ |
| description | Diabetic kidney disease (DKD) is currently one of the leading causes of end-stage renal disease (ESRD). Mitochondrial dysfunction in podocyte is involve in DKD development. However, whether early mitochondrial stabilization delays or reverses DKD progression has not been elucidated. SS31 is a novel tetrapeptide compound that targets the inner mitochondrial membrane and protects mitochondria by reducing ROS and inhibiting cardiolipin oxidation. Our study discovered that SS31 might have a long-term podocyte protection in DKD. In this study, we examined the glomerular pathological damage and proteinuria at different stages of diabetes. Results revealed that podocyte mitochondrial injury appeared at the early stage of DKD. Early treatment with SS31 could protect podocyte and alleviate the development of DKD via inhibiting OMA1-mediated hydrolysis of OPA1. Those data indicate that SS31 might be a promising agent in delaying the development of DKD and OMA1-mediated hydrolysis of OPA1 in mitochondria, and SS31 is a novel therapeutic target for the treatment of DKD. |
| first_indexed | 2024-04-13T15:57:55Z |
| format | Article |
| id | doaj.art-eac473ebae2248999baa87129ece1678 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-13T15:57:55Z |
| publishDate | 2022-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-eac473ebae2248999baa87129ece16782022-12-22T02:40:38ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-01-011210.3389/fphar.2021.707006707006SS31 Ameliorates Podocyte Injury via Inhibiting OMA1-Mediated Hydrolysis of OPA1 in Diabetic Kidney DiseaseQianqian YangWenjia XieXiao WangJing LuoYang ZhouHongdi CaoQi SunLei JiangJunwei YangDiabetic kidney disease (DKD) is currently one of the leading causes of end-stage renal disease (ESRD). Mitochondrial dysfunction in podocyte is involve in DKD development. However, whether early mitochondrial stabilization delays or reverses DKD progression has not been elucidated. SS31 is a novel tetrapeptide compound that targets the inner mitochondrial membrane and protects mitochondria by reducing ROS and inhibiting cardiolipin oxidation. Our study discovered that SS31 might have a long-term podocyte protection in DKD. In this study, we examined the glomerular pathological damage and proteinuria at different stages of diabetes. Results revealed that podocyte mitochondrial injury appeared at the early stage of DKD. Early treatment with SS31 could protect podocyte and alleviate the development of DKD via inhibiting OMA1-mediated hydrolysis of OPA1. Those data indicate that SS31 might be a promising agent in delaying the development of DKD and OMA1-mediated hydrolysis of OPA1 in mitochondria, and SS31 is a novel therapeutic target for the treatment of DKD.https://www.frontiersin.org/articles/10.3389/fphar.2021.707006/fullSS31mitochondriaOma1OPA1podocytediabetic nephropathy |
| spellingShingle | Qianqian Yang Wenjia Xie Xiao Wang Jing Luo Yang Zhou Hongdi Cao Qi Sun Lei Jiang Junwei Yang SS31 Ameliorates Podocyte Injury via Inhibiting OMA1-Mediated Hydrolysis of OPA1 in Diabetic Kidney Disease Frontiers in Pharmacology SS31 mitochondria Oma1 OPA1 podocyte diabetic nephropathy |
| title | SS31 Ameliorates Podocyte Injury via Inhibiting OMA1-Mediated Hydrolysis of OPA1 in Diabetic Kidney Disease |
| title_full | SS31 Ameliorates Podocyte Injury via Inhibiting OMA1-Mediated Hydrolysis of OPA1 in Diabetic Kidney Disease |
| title_fullStr | SS31 Ameliorates Podocyte Injury via Inhibiting OMA1-Mediated Hydrolysis of OPA1 in Diabetic Kidney Disease |
| title_full_unstemmed | SS31 Ameliorates Podocyte Injury via Inhibiting OMA1-Mediated Hydrolysis of OPA1 in Diabetic Kidney Disease |
| title_short | SS31 Ameliorates Podocyte Injury via Inhibiting OMA1-Mediated Hydrolysis of OPA1 in Diabetic Kidney Disease |
| title_sort | ss31 ameliorates podocyte injury via inhibiting oma1 mediated hydrolysis of opa1 in diabetic kidney disease |
| topic | SS31 mitochondria Oma1 OPA1 podocyte diabetic nephropathy |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2021.707006/full |
| work_keys_str_mv | AT qianqianyang ss31amelioratespodocyteinjuryviainhibitingoma1mediatedhydrolysisofopa1indiabetickidneydisease AT wenjiaxie ss31amelioratespodocyteinjuryviainhibitingoma1mediatedhydrolysisofopa1indiabetickidneydisease AT xiaowang ss31amelioratespodocyteinjuryviainhibitingoma1mediatedhydrolysisofopa1indiabetickidneydisease AT jingluo ss31amelioratespodocyteinjuryviainhibitingoma1mediatedhydrolysisofopa1indiabetickidneydisease AT yangzhou ss31amelioratespodocyteinjuryviainhibitingoma1mediatedhydrolysisofopa1indiabetickidneydisease AT hongdicao ss31amelioratespodocyteinjuryviainhibitingoma1mediatedhydrolysisofopa1indiabetickidneydisease AT qisun ss31amelioratespodocyteinjuryviainhibitingoma1mediatedhydrolysisofopa1indiabetickidneydisease AT leijiang ss31amelioratespodocyteinjuryviainhibitingoma1mediatedhydrolysisofopa1indiabetickidneydisease AT junweiyang ss31amelioratespodocyteinjuryviainhibitingoma1mediatedhydrolysisofopa1indiabetickidneydisease |